You have read all your free articles, to continue reading subscribe to read the rest of this content.
Calliditas Therapeutics has announced that the U.S. Food and Drug Administration has accepted the submission and granted Priority Review for the New Drug Application (NDA) for Nefecon, a down regulator of IgA1 for the treatment of IgA nephropathy (IgAN.) The FDA has set a Prescription Drug User FAlready a subscriber…
Ultomiris has been approved for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease. “Since bringing forward thefirst complement inhibitor, we’ve continuedAlready a subscriber Login You have read all your free articles, to continue…
Novo Nordisk increased operating profit by 43% in 2015 to DKK 49,4 billion and the company achieved its four long-term financial targets established in January 2013. Adjusted for the DKK 2.4 billion non-recurring income related to the partial divestment of NNIT, the operating margin was 43.6% corAlready a subscriber Login…
Medivir announces that Janssen Pharmaceuticals has decided to terminate the license that it holds for simeprevir due to Janssen's assessment of market demand. The termination of the license will become effective in June 2018 and Medivir will continue to receive royalties on any remaining sales oAlready a subscriber Login You have…
